Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV

This article was originally published in The Pink Sheet Daily

Executive Summary

Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.

You may also be interested in...



Tivicay Launch Returns ViiV To HIV Spotlight And Growth

The launch of Tivicay, a once-daily integrase inhibitor, will be the driving force behind the HIV specialist’s return to growth, anticipated in 2014, according to CEO Dominique Limet.

ViiV Secures Its First New Drug Approval With Tivicay

The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.

Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning

TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)

Topics

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel